Rationale and design of REAC-TAVI 2: Single antiplatelet treatment with ticagrelor vs aspirin after transcatheter aortic valve implantation.
Hemelrijk KI, Jimenez-Diaz VA, Vilchez JP, Oteo JF, Gomez-Blazquez I, Sabate M, Vilalta V, Jofresa AB, Asmarats L, Amat-Santos IJ, Tello-Montoliu A, de la Torre Hernandez JM, Flores X, Gheorghe L, Peral V, Muñoz-Garcia AJ, Alfonso F, Tirado-Conte G, Brugaletta S, Veiga G, Rodriguez-Gabella T, Regueiro A, De Lara JG, Valle-Fernandez RD, Nodar JMR, Mazuecos JJ, Pan M, Baz JA, Fernández JFD, Guerreiro C, Jorge E, Silva MT, Marques JS, Rodrigues I, Neves D, Braga JP, Testa L, Costa G, Stefanini G, Pesarini G, Sisinni A, Capodanno D, Ribichini F, Salvadores PJ, Delewi R, Angiolillo DJ, Garcia-Garcia HM, Iñiguez A, Nombela-Franco L; REAC-TAVI 2 Investigators.
Hemelrijk KI, et al. Among authors: marques js.
Am Heart J. 2026 Feb;292:107293. doi: 10.1016/j.ahj.2025.107293. Epub 2025 Nov 1.
Am Heart J. 2026.
PMID: 41177202